<track id="ine19"><span id="ine19"></span></track>
<source id="ine19"></source>
<bdo id="ine19"><optgroup id="ine19"></optgroup></bdo>

      Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease.? We currently have 2 products commercialized and 3 drugs approved in the U.S.? Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.
      Drug
      Indication
      Topic
      ZL-2306 (Niraparib)
      Ovarian Cancer
      To evaluate the efficacy and safety of ZL-2306 for maintenance treatment of platinum-sensitive recurrent ovarian cancer
      ZL-2306 (Niraparib)
      Ovarian Cancer
      To evaluate the efficacy and safety of ZL-2306 for maintenance treatment of ovarian cancer patients who were responsive to first-line chemotherapy
      FPA-144
      Gastric Cancer & Gastroesophageal Cancer
      Evaluation of I/III randomized controlled trial of FPA144 combined with FOLFOX6 in the treatment of advanced gastric cancer
      ZL-2301 (Brivanib)
      Hepatocellular Carcinoma
      The efficacy, safety and pharmacokinetics of ZL-2301 in advanced liver cancer
      For more information about the above trials, please visit http://www.chinadrugtrials.org.cn/
      分分28